2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1066

Invention and Phenotypic Evaluation of Human IgG4-Knock-in Mice

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1097

Investigating Opportunities for Cost Conscious Care: A Review of Physician Practice in Ordering Anti-Nuclear Antibody Testing at an Academic Community Hospital

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1269

Investigating Time Trends in Incident Pediatric Lupus across Ethnic Groups in Toronto, Canada—a Large, Multiethnic Metropolitan Area

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

9:00AM-11:00AM: Abstract Number: 1017

Investigation of Differential Methylation As a Potential Biomarker of Methotrexate Response in Patients with Rheumatoid Arthritis

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1455

Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1138

Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1742

Involvement of T Helper 17 Cells in Inflammatory Arthritis Depends on the Host Intestinal Microbiota

T Cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1356

Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1340

Is Depression in Patients with Rheumatoid Arthritis Associated with Disease Activity? Comparative Study between Germany and Brazil

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 980

Is Intra-Articular Injection of Synvisc Associated with a Delay to Knee Arthroplasty in Knee OA Patients?

Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1438

Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1353

Is Joint Damage Due to Secondary Osteoarthritis (OA) Clinically As Important As Inflammation in Contemporary Management of Rheumatoid Arthritis (RA)?

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1512

Is Sacroiliac Imaging the All-Decisive Factor in the Diagnosis of Early Axial Spondyloarthritis? Data from the Spondyloarthritis Caught Early (SPACE) Cohort

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1491

Is There a Seasonal Effect on Fatigue, Pain, and Dryness in Primary Sjögren’s Syndrome? Data from the Prospective Assess Cohort and from 3 Randomized Controlled Trials

Sjögren's Syndrome Poster II: Clinical Research

9:00AM-11:00AM: Abstract Number: 1569

Isotretinoin Induced Seronegative Spondyloarthropathy: Magnetic Resonance Imaging As Diagnostic and Prognostic Biomarker

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].